Traction Bronchiectasis/Bronchiolectasis is Associated with Interstitial Lung Abnormality Mortality

Tomoyuki Hida; Mizuki Nishino; Takuya Hino; Junwei Lu; Rachel K. Putman; Elias F. Gudmundsson; Tetsuro Araki; Vladimir I. Valtchinov; Osamu Honda; Masahiro Yanagawa; Yoshitake Yamada; Akinori Hata; Masahiro Jinzaki; Noriyuki Tomiyama; Hiroshi Honda; Raul San Jose Estepar; George R. Washko; Takeshi Johkoh; David C. Christiani; David A. Lynch; Vilmundur Gudnason; Gunnar Gudmundsson; Gary M. Hunninghake; Hiroto Hatabu

doi:10.1016/j.ejrad.2020.109073

Traction Bronchiectasis/Bronchiolectasis is Associated with Interstitial Lung Abnormality Mortality

Tomoyuki Hida, Mizuki Nishino, Takuya Hino, Junwei Lu, Rachel K. Putman, Elias F. Gudmundsson, Tetsuro Araki, Vladimir I. Valtchinov, Osamu Honda, Masahiro Yanagawa, Yoshitake Yamada, Akinori Hata, Masahiro Jinzaki, Noriyuki Tomiyama, Hiroshi Honda, Raul San Jose Estepar, George R. Washko, Takeshi Johkoh, David C. Christiani, David A. LynchVilmundur Gudnason, Gunnar Gudmundsson, Gary M. Hunninghake, Hiroto Hatabu

Department of Radiology (Diagnostic Radiology)

Research output: Contribution to journal › Article › peer-review

22 Citations (Scopus)

Abstract

Purpose: To investigate if the presence and severity of traction bronchiectasis/bronchiolectasis are associated with poorer survival in subjects with ILA. Method: The study included 3,594 subjects (378 subjects with ILA and 3,216 subjects without ILA) in AGES-Reykjavik Study. Chest CT scans of 378 subjects with ILA were evaluated for traction bronchiectasis/bronchiolectasis, defined as dilatation of bronchi/bronchioles within areas demonstrating ILA. Traction bronchiectasis/bronchiolectasis Index (TBI) was assigned as: TBI = 0, ILA without traction bronchiectasis/bronchiolectasis: TBI = 1, ILA with bronchiolectasis but without bronchiectasis or architectural distortion: TBI = 2, ILA with mild to moderate traction bronchiectasis: TBI = 3, ILA and severe traction bronchiectasis and/or honeycombing. Overall survival (OS) was compared among the subjects in different TBI groups and those without ILA. Results: The median OS was 12.93 years (95%CI; 12.67 – 13.43) in the subjects without ILA; 11.95 years (10.03 – not reached) in TBI-0 group; 8.52 years (7.57 – 9.30) in TBI-1 group; 7.63 years (6.09 – 9.10) in TBI-2 group; 5.40 years (1.85 – 5.98) in TBI-3 group. The multivariable Cox models demonstrated significantly shorter OS of TBI-1, TBI-2, and TBI-3 groups compared to subjects without ILA (P < 0.0001), whereas TBI-0 group had no significant OS difference compared to subjects without ILA, after adjusting for age, sex, and smoking status. Conclusions: The presence and severity of traction bronchiectasis/bronchiolectasis are associated with shorter survival. The traction bronchiectasis/bronchiolectasis is an important contributor to increased mortality among subjects with ILA.

Original language	English
Article number	109073
Journal	European Journal of Radiology
Volume	129
DOIs	https://doi.org/10.1016/j.ejrad.2020.109073
Publication status	Published - 2020 Aug

Keywords

Age Gene/Environment Susceptibility-Reykjavik Study
Interstitial lung abnormality
Pulmonary fibrosis
Traction bronchiectasis
Usual interstitial pneumonia

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.ejrad.2020.109073

Cite this

Hida, T., Nishino, M., Hino, T., Lu, J., Putman, R. K., Gudmundsson, E. F., Araki, T., Valtchinov, V. I., Honda, O., Yanagawa, M., Yamada, Y., Hata, A., Jinzaki, M., Tomiyama, N., Honda, H., Estepar, R. S. J., Washko, G. R., Johkoh, T., Christiani, D. C., ... Hatabu, H. (2020). Traction Bronchiectasis/Bronchiolectasis is Associated with Interstitial Lung Abnormality Mortality. European Journal of Radiology, 129, [109073]. https://doi.org/10.1016/j.ejrad.2020.109073

Hida, T, Nishino, M, Hino, T, Lu, J, Putman, RK, Gudmundsson, EF, Araki, T, Valtchinov, VI, Honda, O, Yanagawa, M, Yamada, Y, Hata, A, Jinzaki, M, Tomiyama, N, Honda, H, Estepar, RSJ, Washko, GR, Johkoh, T, Christiani, DC, Lynch, DA, Gudnason, V, Gudmundsson, G, Hunninghake, GM & Hatabu, H 2020, 'Traction Bronchiectasis/Bronchiolectasis is Associated with Interstitial Lung Abnormality Mortality', European Journal of Radiology, vol. 129, 109073. https://doi.org/10.1016/j.ejrad.2020.109073

@article{195f6ed8b3b04ec7941c470eb01a1b16,

title = "Traction Bronchiectasis/Bronchiolectasis is Associated with Interstitial Lung Abnormality Mortality",

abstract = "Purpose: To investigate if the presence and severity of traction bronchiectasis/bronchiolectasis are associated with poorer survival in subjects with ILA. Method: The study included 3,594 subjects (378 subjects with ILA and 3,216 subjects without ILA) in AGES-Reykjavik Study. Chest CT scans of 378 subjects with ILA were evaluated for traction bronchiectasis/bronchiolectasis, defined as dilatation of bronchi/bronchioles within areas demonstrating ILA. Traction bronchiectasis/bronchiolectasis Index (TBI) was assigned as: TBI = 0, ILA without traction bronchiectasis/bronchiolectasis: TBI = 1, ILA with bronchiolectasis but without bronchiectasis or architectural distortion: TBI = 2, ILA with mild to moderate traction bronchiectasis: TBI = 3, ILA and severe traction bronchiectasis and/or honeycombing. Overall survival (OS) was compared among the subjects in different TBI groups and those without ILA. Results: The median OS was 12.93 years (95%CI; 12.67 – 13.43) in the subjects without ILA; 11.95 years (10.03 – not reached) in TBI-0 group; 8.52 years (7.57 – 9.30) in TBI-1 group; 7.63 years (6.09 – 9.10) in TBI-2 group; 5.40 years (1.85 – 5.98) in TBI-3 group. The multivariable Cox models demonstrated significantly shorter OS of TBI-1, TBI-2, and TBI-3 groups compared to subjects without ILA (P < 0.0001), whereas TBI-0 group had no significant OS difference compared to subjects without ILA, after adjusting for age, sex, and smoking status. Conclusions: The presence and severity of traction bronchiectasis/bronchiolectasis are associated with shorter survival. The traction bronchiectasis/bronchiolectasis is an important contributor to increased mortality among subjects with ILA.",

keywords = "Age Gene/Environment Susceptibility-Reykjavik Study, Interstitial lung abnormality, Pulmonary fibrosis, Traction bronchiectasis, Usual interstitial pneumonia",

author = "Tomoyuki Hida and Mizuki Nishino and Takuya Hino and Junwei Lu and Putman, {Rachel K.} and Gudmundsson, {Elias F.} and Tetsuro Araki and Valtchinov, {Vladimir I.} and Osamu Honda and Masahiro Yanagawa and Yoshitake Yamada and Akinori Hata and Masahiro Jinzaki and Noriyuki Tomiyama and Hiroshi Honda and Estepar, {Raul San Jose} and Washko, {George R.} and Takeshi Johkoh and Christiani, {David C.} and Lynch, {David A.} and Vilmundur Gudnason and Gunnar Gudmundsson and Hunninghake, {Gary M.} and Hiroto Hatabu",

note = "Funding Information: Dr. Nishino is supported by NIH grant R01 CA203636 . Dr. Putman is supported by NIH grant K08 HL140087 . Dr. Gudmundsson is supported by project grant from the Icelandic Research Fund . Dr. Washko is supported by NIH grants R01 HL116473 and R01 HL122464 . Dr. Christiani is supported by NIH ( NCI ) grant # U01CA209414 . The Age, Gene/Environment Susceptibility-Reykjavik Study was supported by NIH contracts N01-AG-1-2100 and HHSN27120120022C, the NIA Intramural Research Program, Hjartavernd (the Icelandic Heart Association), and the Althingi (the Icelandic Parliament). Dr. Gudnason is supported by NIA grant: 27120120022C and project grant from the Icelandic Research Fund. Dr. Hunninghake is supported by NIH grants R01 HL111024 , R01 HL130974 , R01 135142 , and project grant 141513-051 from the Icelandic Research Fund. Funding Information: MN reports personal fees from Daiichi Sankyo, personal fees from AstraZeneca, grants from Research grant to the institution from Merck, grants from Research grant to the institution from Canon Medical systems, grants from Research grant to the institution from AstraZeneca, grants from Research grant to the institution from Daiichi Sankyo, personal fees from Roche, grants from NIH, outside the submitted work; RKP reports grants from NIH, during the conduct of the study; RSJE reports grants from Boehringer Ingelheim, personal fees from Boehringer Ingelheim, personal fees from Chiesi, grants from NHBLI, outside the submitted work; and he is also a founder and co-owner of Quantitative Imaging Solutions which is a company that provides image based consulting and develops software to enable data sharing.; RSJE is also a founder and co-owner of Quantitative Imaging Solutions which is a company that provides image based consulting and develops software to enable data sharing.: Dr. Washko reports grants from NIH, grants and other from Boehringer Ingelheim, other from Quantitative Imaging Solutions, other from PulmonX, grants from BTG Interventional Medicine, grants and other from Janssen Pharmaceuticals, other from GlaxoSmithKline, other from Novartis, other from Vertex, outside the submitted work; and Dr. Washko's spouse works for Biogen.; DAL reports personal fees from Boehringer Ingelheim, personal fees from Parexel, Inc, personal fees from Veracyte, Inc, outside the submitted work; In addition, DAL has a pending patent {"}Systems and methods for automatic detection and quantification of pathology using dynamic feature classification.{"}: GMH reports personal fees from Boehringer-Ingelheim, personal fees from Gerson Lehrman Group, personal fees from Mitsubishi Chemical, outside the submitted work; HH reports grants from Canon Medical System Inc, grants from Konica Minolta Inc, other from Mitsubishi Chemical Inc, other from Canon Medical System Inc, outside the submitted work. Funding Information: Dr. Nishino is supported by NIH grant? R01 CA203636. Dr. Putman is supported by NIH grant K08 HL140087. Dr. Gudmundsson is? supported by project grant from the Icelandic? Research Fund. Dr.? Washko is supported by NIH grants R01 HL116473 and R01 HL122464. Dr. Christiani is supported by NIH (NCI) grant # U01CA209414. The Age,? Gene/Environment Susceptibility-Reykjavik Study was supported by NIH contracts N01-AG-1-?2100 and HHSN27120120022C, the NIA Intramural Research Program, Hjartavernd (the? Icelandic Heart Association), and the Althingi (the Icelandic Parliament). Dr. Gudnason is? supported by NIA grant: 27120120022C and project grant from the Icelandic? Research Fund. Dr. Hunninghake is supported by NIH grants R01 HL111024,? R01 HL130974, R01 135142, and project grant 141513-051 from the Icelandic Research Fund. Publisher Copyright: {\textcopyright} 2020 Elsevier B.V.",

year = "2020",

month = aug,

doi = "10.1016/j.ejrad.2020.109073",

language = "English",

volume = "129",

journal = "European Journal of Radiology",

issn = "0720-048X",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Traction Bronchiectasis/Bronchiolectasis is Associated with Interstitial Lung Abnormality Mortality

AU - Hida, Tomoyuki

AU - Nishino, Mizuki

AU - Hino, Takuya

AU - Lu, Junwei

AU - Putman, Rachel K.

AU - Gudmundsson, Elias F.

AU - Araki, Tetsuro

AU - Valtchinov, Vladimir I.

AU - Honda, Osamu

AU - Yanagawa, Masahiro

AU - Yamada, Yoshitake

AU - Hata, Akinori

AU - Jinzaki, Masahiro

AU - Tomiyama, Noriyuki

AU - Honda, Hiroshi

AU - Estepar, Raul San Jose

AU - Washko, George R.

AU - Johkoh, Takeshi

AU - Christiani, David C.

AU - Lynch, David A.

AU - Gudnason, Vilmundur

AU - Gudmundsson, Gunnar

AU - Hunninghake, Gary M.

AU - Hatabu, Hiroto

N1 - Funding Information: Dr. Nishino is supported by NIH grant R01 CA203636 . Dr. Putman is supported by NIH grant K08 HL140087 . Dr. Gudmundsson is supported by project grant from the Icelandic Research Fund . Dr. Washko is supported by NIH grants R01 HL116473 and R01 HL122464 . Dr. Christiani is supported by NIH ( NCI ) grant # U01CA209414 . The Age, Gene/Environment Susceptibility-Reykjavik Study was supported by NIH contracts N01-AG-1-2100 and HHSN27120120022C, the NIA Intramural Research Program, Hjartavernd (the Icelandic Heart Association), and the Althingi (the Icelandic Parliament). Dr. Gudnason is supported by NIA grant: 27120120022C and project grant from the Icelandic Research Fund. Dr. Hunninghake is supported by NIH grants R01 HL111024 , R01 HL130974 , R01 135142 , and project grant 141513-051 from the Icelandic Research Fund. Funding Information: MN reports personal fees from Daiichi Sankyo, personal fees from AstraZeneca, grants from Research grant to the institution from Merck, grants from Research grant to the institution from Canon Medical systems, grants from Research grant to the institution from AstraZeneca, grants from Research grant to the institution from Daiichi Sankyo, personal fees from Roche, grants from NIH, outside the submitted work; RKP reports grants from NIH, during the conduct of the study; RSJE reports grants from Boehringer Ingelheim, personal fees from Boehringer Ingelheim, personal fees from Chiesi, grants from NHBLI, outside the submitted work; and he is also a founder and co-owner of Quantitative Imaging Solutions which is a company that provides image based consulting and develops software to enable data sharing.; RSJE is also a founder and co-owner of Quantitative Imaging Solutions which is a company that provides image based consulting and develops software to enable data sharing.: Dr. Washko reports grants from NIH, grants and other from Boehringer Ingelheim, other from Quantitative Imaging Solutions, other from PulmonX, grants from BTG Interventional Medicine, grants and other from Janssen Pharmaceuticals, other from GlaxoSmithKline, other from Novartis, other from Vertex, outside the submitted work; and Dr. Washko's spouse works for Biogen.; DAL reports personal fees from Boehringer Ingelheim, personal fees from Parexel, Inc, personal fees from Veracyte, Inc, outside the submitted work; In addition, DAL has a pending patent "Systems and methods for automatic detection and quantification of pathology using dynamic feature classification.": GMH reports personal fees from Boehringer-Ingelheim, personal fees from Gerson Lehrman Group, personal fees from Mitsubishi Chemical, outside the submitted work; HH reports grants from Canon Medical System Inc, grants from Konica Minolta Inc, other from Mitsubishi Chemical Inc, other from Canon Medical System Inc, outside the submitted work. Funding Information: Dr. Nishino is supported by NIH grant? R01 CA203636. Dr. Putman is supported by NIH grant K08 HL140087. Dr. Gudmundsson is? supported by project grant from the Icelandic? Research Fund. Dr.? Washko is supported by NIH grants R01 HL116473 and R01 HL122464. Dr. Christiani is supported by NIH (NCI) grant # U01CA209414. The Age,? Gene/Environment Susceptibility-Reykjavik Study was supported by NIH contracts N01-AG-1-?2100 and HHSN27120120022C, the NIA Intramural Research Program, Hjartavernd (the? Icelandic Heart Association), and the Althingi (the Icelandic Parliament). Dr. Gudnason is? supported by NIA grant: 27120120022C and project grant from the Icelandic? Research Fund. Dr. Hunninghake is supported by NIH grants R01 HL111024,? R01 HL130974, R01 135142, and project grant 141513-051 from the Icelandic Research Fund. Publisher Copyright: © 2020 Elsevier B.V.

PY - 2020/8

Y1 - 2020/8

N2 - Purpose: To investigate if the presence and severity of traction bronchiectasis/bronchiolectasis are associated with poorer survival in subjects with ILA. Method: The study included 3,594 subjects (378 subjects with ILA and 3,216 subjects without ILA) in AGES-Reykjavik Study. Chest CT scans of 378 subjects with ILA were evaluated for traction bronchiectasis/bronchiolectasis, defined as dilatation of bronchi/bronchioles within areas demonstrating ILA. Traction bronchiectasis/bronchiolectasis Index (TBI) was assigned as: TBI = 0, ILA without traction bronchiectasis/bronchiolectasis: TBI = 1, ILA with bronchiolectasis but without bronchiectasis or architectural distortion: TBI = 2, ILA with mild to moderate traction bronchiectasis: TBI = 3, ILA and severe traction bronchiectasis and/or honeycombing. Overall survival (OS) was compared among the subjects in different TBI groups and those without ILA. Results: The median OS was 12.93 years (95%CI; 12.67 – 13.43) in the subjects without ILA; 11.95 years (10.03 – not reached) in TBI-0 group; 8.52 years (7.57 – 9.30) in TBI-1 group; 7.63 years (6.09 – 9.10) in TBI-2 group; 5.40 years (1.85 – 5.98) in TBI-3 group. The multivariable Cox models demonstrated significantly shorter OS of TBI-1, TBI-2, and TBI-3 groups compared to subjects without ILA (P < 0.0001), whereas TBI-0 group had no significant OS difference compared to subjects without ILA, after adjusting for age, sex, and smoking status. Conclusions: The presence and severity of traction bronchiectasis/bronchiolectasis are associated with shorter survival. The traction bronchiectasis/bronchiolectasis is an important contributor to increased mortality among subjects with ILA.

AB - Purpose: To investigate if the presence and severity of traction bronchiectasis/bronchiolectasis are associated with poorer survival in subjects with ILA. Method: The study included 3,594 subjects (378 subjects with ILA and 3,216 subjects without ILA) in AGES-Reykjavik Study. Chest CT scans of 378 subjects with ILA were evaluated for traction bronchiectasis/bronchiolectasis, defined as dilatation of bronchi/bronchioles within areas demonstrating ILA. Traction bronchiectasis/bronchiolectasis Index (TBI) was assigned as: TBI = 0, ILA without traction bronchiectasis/bronchiolectasis: TBI = 1, ILA with bronchiolectasis but without bronchiectasis or architectural distortion: TBI = 2, ILA with mild to moderate traction bronchiectasis: TBI = 3, ILA and severe traction bronchiectasis and/or honeycombing. Overall survival (OS) was compared among the subjects in different TBI groups and those without ILA. Results: The median OS was 12.93 years (95%CI; 12.67 – 13.43) in the subjects without ILA; 11.95 years (10.03 – not reached) in TBI-0 group; 8.52 years (7.57 – 9.30) in TBI-1 group; 7.63 years (6.09 – 9.10) in TBI-2 group; 5.40 years (1.85 – 5.98) in TBI-3 group. The multivariable Cox models demonstrated significantly shorter OS of TBI-1, TBI-2, and TBI-3 groups compared to subjects without ILA (P < 0.0001), whereas TBI-0 group had no significant OS difference compared to subjects without ILA, after adjusting for age, sex, and smoking status. Conclusions: The presence and severity of traction bronchiectasis/bronchiolectasis are associated with shorter survival. The traction bronchiectasis/bronchiolectasis is an important contributor to increased mortality among subjects with ILA.

KW - Age Gene/Environment Susceptibility-Reykjavik Study

KW - Interstitial lung abnormality

KW - Pulmonary fibrosis

KW - Traction bronchiectasis

KW - Usual interstitial pneumonia

UR - http://www.scopus.com/inward/record.url?scp=85085299274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085299274&partnerID=8YFLogxK

U2 - 10.1016/j.ejrad.2020.109073

DO - 10.1016/j.ejrad.2020.109073

M3 - Article

C2 - 32480316

AN - SCOPUS:85085299274

SN - 0720-048X

VL - 129

JO - European Journal of Radiology

JF - European Journal of Radiology

M1 - 109073

ER -

Traction Bronchiectasis/Bronchiolectasis is Associated with Interstitial Lung Abnormality Mortality

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this